Key Highlights
- 32.19% of the float in Intellia (NASDAQ:NTLA) is sold short, with 9.5 days to cover, per published market data (October 16, 2026 intraday). FINRA data for September 15, 2026 recorded 46,681,609 shares short, equal to 34.52% of float.
- March 10, 2027 is the FDA action date for lonvo-z in hereditary angioedema, per the 8-K dated September 8, 2026. The FDA accepted the application with Priority Review and told Intellia (NASDAQ:NTLA) it does not currently plan an advisory committee.
- USD 628.4 million of cash and marketable securities at June 30, 2026 is expected to fund Intellia (NASDAQ:NTLA) at least into 2028, excluding lonvo-z revenue. Second quarter net loss was USD 106.6 million, per the 8-K dated August 6, 2026.
- USD 11.38 is the October 16, 2026 quote, a market capitalisation of USD 1.59 billion. The October 15 close of USD 11.34 sat at the bottom of a 50-day range of USD 11.34 to USD 13.51, per published market data.
Short Interest Setup Before a Binary Date
A short position into an FDA date is a bet that approval is priced in or that the market sells the news. FINRA data show short interest rose 6.27% to 46,681,609 shares between August 31 and September 15, 2026, and days to cover reached 14.1 on a 5.09 million share average volume. At USD 11.38, that position is worth USD 531 million, own arithmetic. High days to cover is the key mechanism: shorts cannot exit quickly, so good news can force buying into thin supply.
Catalyst Review and Clinical Risk
The identified driver is the September 8, 2026 acceptance of the lonvo-z application with Priority Review. Intellia reported Phase 3 results earlier in 2026: an 87% reduction in monthly attack rates against placebo and 62% of patients attack-free over six months, as summarised in May 2026. No new catalyst was identified for October 16. The short case sits in the second program: the August 6 release said the highest liver transaminase elevations appeared in patients with one HLA allele, and Phase 3 enrolment in nex-z has resumed.
Cash, Dilution and Monitoring Points
Cash of USD 628.4 million equals 39.5% of market capitalisation, own arithmetic. Net loss for the six months was USD 202.9 million, so the runway is a company estimate that depends on spending discipline. Approval can also trigger an equity raise, which is the standard way shorts hedge a positive outcome. Insiders sold USD 23,170 of stock over three months. Dated items: Jing Marantz becomes Chief Medical Officer on October 26, 2026, estimated earnings fall on November 5, 2026, and the FDA date follows on March 10, 2027.
Where Things Stand
A squeeze is possible but not yet signalled. Intellia (NASDAQ:NTLA) has a 32.19% short float, a Priority Review date of March 10, 2027 and USD 628.4 million of cash, yet the stock closed at the bottom of its 50-day range on October 15, 2026, so shorts are winning at present. Covering would most plausibly begin if the market starts to price approval ahead of the decision, or if nex-z enrolment news improves. The next dated tests are third quarter results, estimated for November 5, 2026, and the FDA action on March 10, 2027.





_11_13_2026_20_30_45_840725.jpg)
Please wait processing your request...